Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.

Autor:	O'Neill BT; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Groton , Connecticut 06340 , United States., Beck EM; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Butler CR; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Nolan CE; Internal Medicine , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Gonzales C; Internal Medicine , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Zhang L; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Doran SD; Medicine Design, Pharmacokinetics, Dynamics and Metabolism , Pfizer Inc. , Groton , Connecticut 06340 , United States., Lapham K; Medicine Design, Pharmacokinetics, Dynamics and Metabolism , Pfizer Inc. , Groton , Connecticut 06340 , United States., Buzon LM; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Groton , Connecticut 06340 , United States., Dutra JK; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Groton , Connecticut 06340 , United States., Barreiro G; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Hou X; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Martinez-Alsina LA; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Groton , Connecticut 06340 , United States., Rogers BN; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Villalobos A; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Murray JC; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Groton , Connecticut 06340 , United States., Ogilvie K; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Groton , Connecticut 06340 , United States., LaChapelle EA; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Groton , Connecticut 06340 , United States., Chang C; Medicine Design, Pharmacokinetics, Dynamics and Metabolism , Pfizer Inc. , Groton , Connecticut 06340 , United States., Lanyon LF; Discovery Sciences, Primary Pharmacology , Pfizer Inc. , Groton, Connecticut 06340 , United States., Steppan CM; Discovery Sciences, Primary Pharmacology , Pfizer Inc. , Groton, Connecticut 06340 , United States., Robshaw A; Internal Medicine , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Hales K; Internal Medicine , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Boucher GG; Drug Safety Research and Development , Pfizer Inc. , Groton , Connecticut 06340 , United States., Pandher K; Drug Safety Research and Development , Pfizer Inc. , Groton , Connecticut 06340 , United States., Houle C; Drug Safety Research and Development , Pfizer Inc. , Groton , Connecticut 06340 , United States., Ambroise CW; Internal Medicine , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Karanian D; Drug Safety Research and Development , Pfizer Inc. , Groton , Connecticut 06340 , United States., Riddell D; Internal Medicine , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Bales KR; Internal Medicine , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States., Brodney MA; Medicine Design, Medicinal Chemistry , Pfizer Inc. , Cambridge , Massachusetts 02139 , United States.
Jazyk:	angličtina
Zdroj:	Journal of medicinal chemistry [J Med Chem] 2018 May 24; Vol. 61 (10), pp. 4476-4504. Date of Electronic Publication: 2018 Apr 17.
DOI:	10.1021/acs.jmedchem.8b00246
Abstrakt:	A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2. The potential liabilities of inhibiting BACE2 chronically have only recently begun to emerge as BACE2 impacts the processing of the premelanosome protein (PMEL17) and disrupts melanosome morphology resulting in a depigmentation phenotype. Herein, we describe the identification of clinical candidate PF-06751979 (64), which displays excellent brain penetration, potent in vivo efficacy, and broad selectivity over related aspartyl proteases including BACE2. Chronic dosing of 64 for up to 9 months in dog did not reveal any observation of hair coat color (pigmentation) changes and suggests a key differentiator over current BACE1 inhibitors that are nonselective against BACE2 in later stage clinical development.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu